Creative Planning Oncternal Therapeutics, Inc. Transaction History

Creative Planning

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 21, 2023	BUY	$0.28 - $0.79 $0 - $1	2 Added 0.01%	39,318 $13,000
Q4 2022 Feb 10, 2023	SELL	$0.86 - $22.2 $103 - $2,664	-120 Reduced 0.3%	39,316 $39,000
Q2 2022 Aug 15, 2022	BUY	$0.7 - $1.56 $84 - $187	120 Added 0.31%	39,436 $44,000
Q1 2022 May 16, 2022	SELL	$1.37 - $2.43 $164 - $291	-120 Reduced 0.3%	39,316 $55,000
Q4 2021 Feb 11, 2022	SELL	$2.27 - $4.39 $10,442 - $20,194	-4,600 Reduced 10.45%	39,436 $90,000
Q3 2021 Nov 10, 2021	BUY	$3.37 - $4.76 $70,557 - $99,660	20,937 Added 90.64%	44,036 $184,000
Q2 2021 Aug 04, 2021	SELL	$4.75 - $9.39 $221,103 - $437,085	-46,548 Reduced 66.83%	23,099 $110,000
Q1 2021 Apr 30, 2021	SELL	$4.59 - $9.04 $188,557 - $371,363	-41,080 Reduced 37.1%	69,647 $579,000
Q4 2020 Jan 29, 2021	SELL	$1.51 - $6.3 $569,285 - $2.38 Million	-377,010 Reduced 77.3%	110,727 $543,000
Q1 2020 May 05, 2020	BUY	$2.49 - $4.39 $25,627 - $45,181	10,292 Added 2.16%	487,737 $1.43 Million
Q3 2019 Nov 01, 2019	BUY	$3.87 - $6.13 $1.85 Million - $2.93 Million	477,445 New	477,445 $2.39 Million

362K

Ticker ONCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,517,200
Market Cap $29.4M
Description
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a smal...

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

Stay updated on Creative Planning with notifications on news.